Новые направления в терапии хронического гепатита В
- Авторы: Омарова Х.Г.1, Макашова В.В.1
-
Учреждения:
- ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора
- Выпуск: Том 9, № 3 (2019)
- Страницы: 84-91
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2226-6976/article/view/323299
- DOI: https://doi.org/10.18565/epidem.2019.9.3.84-91
- ID: 323299
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
В обзоре литературы приводятся данные о перспективных препаратах, находящихся на разных стадиях исследования, для лечения больных хроническим гепатитом В.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
Хадижат Гаджиевна Омарова
ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора
Email: omarova71@inbox.ru
научный сотрудник
Вера Васильевна Макашова
ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора
Email: veramakashova@yandex.ru
д.м.н., профессор, ведущий научный сотрудник
Список литературы
- Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 286 с
- Ющук Н.Д., Климова Е.А., Знойко О.О. Вирусные гепатиты. Клиника, диагностика, лечение. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015. 302 с
- Luo Z., Xie Y., Deng M., Zhou X., Ruan B. Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur. J. Gastroenterol. Hepatol 2011; 23(8): 695-700.
- Hahne S.J., Veldhuijzen I.K., Wiessing L., Lim T.A., Salminen M., Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect. Dis. 2013; 13: 181.
- Davison S.A., Strasser S.I. Ordering and interpreting hepatitis B serology. BMJ (Clinical research ed.) 2014; 348: 2522.
- Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S.F. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007; 45(4): 1056-75.
- McMahon B.J. Chronic hepatitis B virus infection. Med. Clin. North Am. 2014; 98(1): 39-54.
- Ganem D., Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. New Engl. J. Med. 2004; 350(11): 1118-29.
- Thiele M., Gluud L.L., Fialla A.D., Dahl E.K., Krag A. Large variations in risk of hepatocellular carcinoma and mortality in treatment naive hepatitis B patients: systematic review with meta-analyses. PLoS One 2014; 9(9): e107177.
- Yang Y.F., Zhao W., Zhong Y.D., Xia H.M., Shen L., Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J. Viral. Hepat. 2009; 16(4): 265-71.
- D’Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 2006; 44(1): 217-31.
- Chu C.M., Liaw Y.F. Hepatitis B virus-related cirrhosis: natural history and treatment. Seminars in Liver Disease 2006; 26(2): 142-52.
- Yang L.S., Shan L.L., Saxena A., Morris D.L. Liver transplantation: a systematic review of long-term quality of life. Liver Int. 2014; 34(9): 1298-313.
- Duffy J.P., Kao K., Ko C.Y., Farmer D.G., McDiarmid S.V., Hong J.C. et al. Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. Annals of Surgery 2010; 252(4): 652-61.
- Scientific Registry of Transplant Recipients. OPTN/SRTR 2012 annual data report: liver, 2012. http://srtr.transplant.hrsa. gov/annual_reports/2012/pdf/ 03_liver_ 13.pdf
- Schoening W.N., Buescher N., Rademacher S., Andreou A., Kuehn S., Neuhaus R. et al. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am. J. Transplant. 2013; 13 (9): 2384-94.
- Исаков В.А. Стратегия лечения хронического гепатита В. Клиническая гастроэнтерология и гепатология. Русское издание 2013; (3): 112-4.
- European Association for the Study of the Liver (EASL) Clinical Practice Guidelines: Management of chronic hepatitis В virus infection. J. Hepatol. 2012; 57: 167-85.
- McMahon B.J. AASLD practice guidelines. Chronic hepatitis B: update 2009. https://www.aasld.org/sites/default/ files/guideline_documents/Chronic HepatitisB2009.pdf
- Dienstag J.L. Hepatitis B virus infection. New Engl. J. Med. 2008; 359(14): 1486-500.
- NCBI. Interferons, 2014. https://www.ncbi.nlm.nih.gov/ mesh/68007372
- Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436(7053): 967-72.
- Anonymous. Interferon production by genetic engineering. Brit. Med. J. (Clinical research ed.) 1981; 282(6265): 674-5.
- Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E. et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chemistry 2001; 12(2): 195-202.
- Sweetman S., ed. Martindale: the complete drug reference (online version), 37th edition, 2011. http://www.pharmpress. com/product/MC_MART/martindale-the-complete-drug-reference
- NCBI. Thymosins, 2014. www.ncbi.nlm.nih.gov/mesh/68013947
- Li J., Liu C.H., Wang F.S. Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides 2010; 31(11): 2151-8.
- Чуланов В.П. Проблемы лекарственной резистентности при противовирусной терапии хронического гепатита В. Клиническая гастроэнтерология и гепатология. Русское издание. 2011; 4(3): 167-72.
- Chang T.T., Liaw Y.F., Wu S.S., Schiff E., Han K.H., Lai C.L. et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
- Schiff E.R., Lee S.S., Chao Y.C., Kew Yoon S., Bessone F., Wu S.S. et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2011; (9): 274-6.
- Marcellin R., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
- Mellerup M.T., Krogsgaard K., Mathurin P., Gluud C., Poynard T. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database of Systematic Reviews 2005, Issue 3. DOI:10.1002/ 14651858.CD000345.pub2.
- Wu T., Xie L., Liu G.J., Hao B., Harrison R.A. Bicyclol for chronic hepatitis B.Cochrane Database of Systematic Reviews 2006, Issue 4. DOI:10.1002/ 14651858.CD004480.pub2
- Xia Y., Luo H., Liu J.P., Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2011, Issue 4. doi: 10.1002/14651858. CD008960.pub2
- Xia Y., Luo H., Liu J.P., Gluud C. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2013, Issue 4. doi: 10.1002/14651858.CD009004.pub2
- Volz T., Giersch K., Allweiss L., Bhadra O.D., Petersen J., Lohse A.W. et al. Myrcludex-B inhibits establishment of HDV super-infection in HBV infected mice and reduces HDV viremia in stably HBV/HDV coinfected mice. J. Hepatol. 2015; 62(Abstr): S514.
- Bogomolov P., Alexandrov A., Voronkova N., Macievich M., Kokina K., Petrachenkova M. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J. Hepatol. 2016; 65(3): 490-8. doi: 10.1016/j.jhep. 2016.04.016.
- Yurdaydin C. et al. Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis. EASL 50th International Liver Congress, Vienna, 2015. Abstract O118.
- http://tetralogicpharma.com/birinapant-publications-presentations/
- Ebert G., Preston S., Allison C., Cooney J., Toe J.G., Stutz M.D. et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc. Natl. Acad. Sci. USA 2015; 112: 5797-802. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4426461/
- Yang P.L., Althage A., Chung J., Maier H., Wieland S., Isogawa M., Chisari F.V. Immune effectors required for hepatitis B virus clearance. Proc. Natl. Acad. Sci. USA 2010; 107(2): 798802. http://www.ncbi. nlm.nih.gov/pmc/articles/PMC2818933/
- Lee Y.H., Bae S.C., Song G.G. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin. Exp. Rheumatol. 2013; 31(1): 118-121. http:// www.ncbi.nlm.nih.gov/pubmed/23111095
- Lan J.L., Chen Y.M., Hsieh T.Y., Chen Y.H., Hsieh C.W., Chen D.Y., Yang S. S. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann. Rheum. Dis. 2011; 70(10): 1719-25. http://www.ncbi.nlm.nih.gov/pubmed/ 21719446
- Silke J. The regulation of TNF signalling: What a tangled web we weave. Curr. Opin. Immunol. 2011; 23(5): 620-6. http:// www.ncbi.nlm.nih. gov/pubmed/21920725
- Allensworth J.L., Sauer S.J., Lyerly H.K., Morse M.A., Devi G.R. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-a-independent mechanism. Breast. Cancer Res. Treat. 2013; 137(2): 359-71. http://www. ncbi.nlm.nih.gov/pubmed/23225169
- Carter B.Z., Mak P.Y., Mak D.H., Shi Y., Qiu Y., Bogenberger J.M. et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J. Natl. Cancer Inst. 2014; 106(2): djt440. http://www.ncbi.nlm.nih.gov/ubmed/24526787
- Condon S.M., Mitsuuchi Y., Deng Y., La Porte M.G., Rippin S.R., Haimowitz T. et al. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J. Med. Chem. 2014; 57(9): 3666-77. http://www.ncbi.nlm.nih.gov/pubmed/24684347
- Krepler C., Chunduru S.K., Halloran M.B., He X., Xiao M., Vultur A. et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin. Cancer Res. 2013; 19(7): 1784-94. http://www.ncbi.nlm.nih. gov/pubmed/23403634
- Benetatos C.A., Mitsuuchi Y., Burns J.M., Neiman E.M., Condon S.M., Yu G. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 2014; 13(4): 867-79. http://www.ncbi.nlm.nih.gov/pubmed/24563541
- Ebert G., Allison C., Preston S., Cooney J., Toe J.G., Stutz M.D. et al. Immunology and Inflammation, Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc. Natl. Acad. Sci. USA 2015; 112(18): 5803-8. doi: 10.1073/pnas.1502400112, PMCID: PMC4426438. http://www. ncbi.nlm.nih.gov/pmc/articles/PMC4426461/
- Lin Y. J., Huang L. R., Yang H. C., Tzeng H. T., Hsu P. N., Wu H. L., et al. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc. Natl. Acad. Sci. USA 2010; 107(20): 9340-5. http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2889105/
- Huang L.R., Wu H.L., Chen P.J., Chen D.S. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 2006; 103(47): 17862-7. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC1635544/
- Ahmed M., Wang F., Levin A., Le C., Eltayebi Y., Houghton M., Tyrrell L., Barakat K. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. http://dx.doi.org/10.1016/j. drudis.2015.01.008
- Sanford J. The Treatment of viral hepatitis. Moscow: Granate, 2016; 27.
- Bazinet M., Pantea V., Cebotarescu V. et al. Significant reduction of HBsAg and HDV-RNA by the nucleic acid polymer rep 2139 in Caucasian patients with chronic HBV/HDV co-infection. J. Hepatol. 2015; 62 (Abstr.): S257. http://www.aasld.org/sites/default/ files/2015SupplementFULLTEXT.pdf.
- Lam A., Ren S., Vogel R., Espiritu Ch., Kelly M., Lau V. et al. Inhibition of hepatitis B virus replication by the HBV core inhibitor NVR 3-778. In: 66th annual meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, CA; Hepatology 2015; 62(Suppl. 1): 223A.
- Li L., Niu C., Daffis S., Ramos H., Salas E., Voitenleitner Ch., Delaney W.E., Fletcher S.P. HBV Does Not Modulate the Transcriptional Response to TLR7-Induced Cytokines in Highly Infected Primary Human Hepatocytes.; Gilead Sciences, Foster City, CA. 224A AASLD Abstracts Hepatology, October, 2015.
- Wang J., Lu F. Dual-gRNAs and gRNA-microRNA (miRNA)-gRNA ternary cassette combined CRISPR/Cas9 system and RNAi approach promotes the clearance of HBV cccDNA. Peking University Health Science Center, Beijing, China. Hepatology 2015; 62(Suppl. 1): 223A
- Sepp-Lorenzino L., Sprague A.G., Mayo T.. GalNAc-siRNA conjugate ALN-HBV targets a highly conserved, pan-genotypic X-orf viral site and mediates profound and durable HBsAg silencing in vitro and in vivo. 224A AASLD Abstracts Hepatology, October, 2015
Дополнительные файлы
![](/img/style/loading.gif)